Physician
Clinton, Robert
Clinton, Robert was paid $3.71M by Medicaid between Aug 2018 and Jul 2023, across 34 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 28% of everything it billed.
33Billing provider infoCLINTON, ROBERT
FAYETTEVILLE, NC 28304
FAYETTEVILLE, NC 28304
33aNPI1235222928assigned 10/02/2006
33bProvider typeDermatology Physician
28Total paid$3.71M
24GClaims116,671
24DCodes billed34
24AFirst – last monthAug 2018 – Jul 2023
Compared with peers
Next to other Dermatology Physician providers in North Carolina
Rank by total paid#6 of 54
Median peer was paid$176K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 403 | $30K | |
| 2019 | 1,647 | $66K | |
| 2020 | 5,308 | $238K | |
| 2021 | 70,827 | $2.21M | |
| 2022 | 36,284 | $1.10M | |
| 2023 | 2,202 | $65K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 28% | 21,123 | 12,357 | $1.03M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 24% | 13,887 | 9,149 | $885K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 18% | 17,210 | 10,133 | $678K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 16% | 23,094 | 14,016 | $581K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 9.3% | 21,146 | 12,375 | $344K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2.3% | 1,694 | 1,273 | $84K |
| M0240 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses | <1% | 129 | 84 | $36K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 328 | 209 | $16K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 44 | 12 | $16K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 86 | 48 | $6K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 233 | 148 | $5K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 14 | 14 | $4K |
22 more codes
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 109 | $3K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 241 | $3K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 352 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 69 | $1K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 73 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 110 | $689.22 |
| 87541 | <1% | 74 | $616.38 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 58 | $612.70 |
| 87556 | <1% | 77 | $555.90 | |
| 87486 | <1% | 69 | $554.30 | |
| 87532 | <1% | 74 | $492.22 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 82 | $417.32 |
| 87581 | <1% | 60 | $403.00 | |
| 87799 | <1% | 31 | $400.04 | |
| 87640 | <1% | 59 | $393.76 | |
| 87496 | <1% | 50 | $372.85 | |
| 94760 | <1% | 15,747 | $324.55 | |
| 87498 | <1% | 44 | $309.17 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 106 | $143.85 |
| 81001 | <1% | 22 | $36.63 | |
| 3008F | 0% | 81 | $0.00 | |
| 2000F | 0% | 95 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.